Essential Thrombocythemia — Risk-Adapted Management & Specialist Care

Essential Thrombocythemia (ET) is a chronic myeloproliferative neoplasm (MPN) characterized by persistent thrombocytosis — an abnormally elevated platelet count (typically >450 × 10⁹/L) — caused by clonal proliferation of megakaryocytes in the bone marrow. It belongs to the BCR-ABL1-negative MPN family, which also includes polycythemia vera (PV) and primary myelofibrosis (PMF).

ET is driven by somatic gain-of-function mutations in the JAK-STAT signaling pathway. The most common driver mutation is JAK2 V617F (present in ~55–60% of cases), followed by CALR mutations (~25–30%) and MPL mutations (~5%). Approximately 10% of ET patients are 'triple-negative,' lacking all three canonical drivers, and are often tested with broader NGS panels to identify alternative mutations.

The primary clinical concerns in ET are thrombosis (arterial and venous) and, less commonly, major hemorrhage. Long-term disease transformation to myelofibrosis or, rarely, acute myeloid leukemia is a recognized risk. Management is individualized based on a risk stratification framework that weighs age, thrombosis history, and molecular profile.

ET is classified primarily by its underlying driver mutation, which has both prognostic and therapeutic implications. The mutation profile influences thrombosis risk, risk of transformation to myelofibrosis, and response to specific therapies including interferon-alpha.

Many patients with ET are asymptomatic at diagnosis, with thrombocytosis found incidentally on a routine blood count. When symptoms occur, they reflect either thrombotic, hemorrhagic, or vasomotor complications of platelet excess and microvascular dysfunction.

ET is caused by somatic mutations that activate the JAK-STAT signaling pathway in hematopoietic stem cells, leading to clonal expansion of megakaryocytes and unregulated platelet production. These mutations are acquired — not inherited — and occur spontaneously in the hematopoietic stem cell compartment.

Diagnosis of ET requires fulfillment of the WHO (2022) criteria, which combine bone marrow morphology, driver mutation status, exclusion of alternative causes of thrombocytosis, and absence of PV, PMF, CML, or MDS criteria. Reactive thrombocytosis must be excluded before an MPN diagnosis is established.

ET does not use a traditional cancer staging system. Instead, patients are stratified into risk groups based on thrombosis probability — the primary driver of treatment decisions. Risk stratification incorporates age, thrombosis history, and, increasingly, molecular driver mutation status (IPSET-thrombosis revised score).

Treatment of ET is guided by individual thrombosis risk stratification. The primary goals are prevention of thrombotic and hemorrhagic events, control of symptoms, and monitoring for long-term disease transformation. Cytoreductive therapy is reserved for high-risk patients; low-risk patients may require aspirin alone or close observation.

For patients who fail or are intolerant of standard hydroxyurea therapy, several second-line and investigational options are available. JAK inhibitors have shown efficacy in high-burden or refractory ET, and novel agents targeting driver mutations are in early clinical evaluation.

Molecular profiling in ET provides diagnostic confirmation, prognostic stratification, and a framework for treatment selection. Driver mutations (JAK2, CALR, MPL) and co-occurring somatic mutations form the molecular landscape that determines individual patient risk and guides therapy.

ET is a lifelong condition with evolving risk that benefits from specialist hematology input, particularly at diagnosis, when standard therapies fail, and when transformation is suspected. Second opinions from experienced MPN centers ensure optimal risk stratification and access to clinical trials.

ET is generally considered a chronic myeloproliferative neoplasm with a relatively indolent course for most patients, particularly those without high-risk features. Life expectancy approaches that of the age-matched general population in low-risk patients. However, cumulative thrombotic events and the risk of transformation to myelofibrosis or AML affect long-term outcomes in a minority of patients. Access to specialist MPN care and optimal risk-stratified management are the most important determinants of individual prognosis.

Living with ET involves lifelong disease management, regular monitoring, and attention to cardiovascular health and quality of life. The chronic nature of the condition and the implications of long-term medication use require ongoing support from a multidisciplinary team.